Patent application number | Description | Published |
20120020958 | FIBCD1 FOR THE PREVENTION AND TREATMENT OF DISEASES - The present invention relates to methods and compositions for the treatment and/or prevention of diseases such as allergic diseases and inflammatory bowel diseases comprising one or more FIBCD1 binding molecules or pharmaceutically acceptable salts, esters, and amides thereof and optionally one or more non-FIBCD1 binding molecules or pharmaceutically acceptable salts, esters, and amides thereof; as well as the use of such pharmaceutical composition for the prevention and/or treatment of diseases such as allergic diseases and inflammatory bowel diseases. FIBCD1 is herein defined as either a transmembrane receptor, the corresponding DNA or the corresponding mRNA as defined by SEQ ID No. 1, 2 and 3 as well as homologous thereof. | 01-26-2012 |
20140120098 | FIBCD1 FOR THE PREVENTION AND TREATMENT OF DISEASES - The present invention relates to methods and compositions for the treatment and/or prevention of diseases such as allergic diseases and inflammatory bowel diseases comprising one or more FIBCD1 binding molecules or pharmaceutically acceptable salts, esters, and amides thereof and optionally one or more non-FIBCD1 binding molecules or pharmaceutically acceptable salts, esters, and amides thereof; as well as the use of such pharmaceutical composition for the prevention and/or treatment of diseases such as allergic diseases and inflammatory bowel diseases. FIBCD1 is herein defined as either a transmembrane receptor, the corresponding DNA or the correspond mRNA as defined by SEQ ID No. 1, 2 and 3 as well as homologous thereof. | 05-01-2014 |
20150361165 | MFAP4 BINDING ANTIBODIES BLOCKING THE INTERACTION BETWEEN MFAP4 AND INTEGRIN RECEPTORS - Microfibrillar-associated protein 4 (MFAP4) binding antibodies are provided to prevent or to inhibit the proliferation of vascular smooth muscle cells and neointima formation in blood vessels. Furthermore, there are provided antibodies that effectively inhibit remodelling of vessels and prevent progression of arteriosclerosis as well as restenosis of vessels. The provided antibodies block the interaction between MF AP4 and integrin receptors. | 12-17-2015 |
Patent application number | Description | Published |
20100154139 | COMPOSITION FOR THE OXIDATION DYEING OF KERATIN FIBERS COMPRISING PARA-AMINOPHENOL, DIPROPYLENE GLYCOL AND AT LEAST ONE ADDITIONAL DYE PRECURSOR - The present disclosure relates to a composition for the oxidation dyeing of keratin fibers, for example, human keratin fibers such as the hair, intended to be mixed at the time of use with an oxidizing agent, comprising: A) at least one oxidation base chosen from para-aminophenols and the addition salts thereof with an acid; B) at least one additional dye precursor different from the at least one oxidation base defined in A); and C) dipropylene glycol; wherein: the at least one oxidation base is present in an amount of greater than or equal to 1.5% by weight, relative to the total weight of the composition; and the dipropylene glycol is present in an amount of greater than or equal to 3.5% by weight, relative to the total weight of the composition. | 06-24-2010 |
20100154142 | Composition for the oxidation dyeing of keratin fibers comprising at least one fatty substance and at least one N,N-bis(beta-hydroxyethyl)-para-phenylenediamine - The present disclosure relates to a composition for the oxidation dyeing of keratin fibers, for example human keratin fibers such as the hair, comprising: at least one fatty substance present in an amount greater than or equal to 20% by weight relative to the total weight of the composition; at least one oxidation base chosen from N,N-(β-hydroxyethyl)-para-phenylenediamines and the addition salts thereof with an acid, at least one dye precursor different than the at least one oxidation base chosen from N,N-(β-hydroxyethyl)-para-phenylenediamines and the addition salts thereof with an acid, at least one oxidizing agent, and optionally at least one alkaline agent. The disclosure also relates to a dyeing or lightening process using it. Another aspect of the disclosure is multi-compartment devices or kits for obtaining, after mixing together the compositions of the compartments, just before its application, a composition according to the disclosure. | 06-24-2010 |
20100162492 | READY-TO-USE COMPOSITION FOR OXIDATION DYEING OF KERATIN FIBERS COMPRISING AT LEAST ONE FATTY SUBSTANCE CHOSEN FROM FATTY AMIDES AND FATTY ACID ESTERS, AT LEAST ONE DYE PRECURSOR, AT LEAST ONE OXIDIZING AGENT AND OPTIONALLY AT LEAST ONE ALKALINE AGENT, AND METHODS AND KITS THEREWITH - Provided is a ready-to-use composition for the oxidation dyeing of keratin fibers, and for example of human keratin fibers such as the hair, comprising: A) at least one fatty substance present in an amount of greater than or equal to 25% by weight relative to the total weight of the ready-to-use composition, at least one of the at least one fatty substance being chosen from fatty amides and fatty acid esters, B) at least one dye precursor, C) at least one oxidizing agent and optionally D) at least one alkaline agent. Also provided is a method of dyeing of keratin fibres, comprising applying a ready-to-use composition to the keratin fibres for a sufficient time to develop the desired coloration, | 07-01-2010 |
20100162493 | COMPOSITION FOR OXIDATION DYEING OF KERATIN FIBERS COMPRISING AT LEAST ONE FATTY SUBSTANCE, AT LEAST ONE OXIDATION BASE, AT LEAST ONE DYE PRECURSOR, AT LEAST ONE OXIDIZING AGENT, AND OPTIONALLY AT LEAST ONE ALKALINE AGENT, AND PROCESSES AND KITS THEREWITH - The disclosure relates to a composition for the oxidation dyeing of keratin fibers comprising: A) at least one fatty substance wherein the at least one fatty substance is present in an amount greater than or equal to 25% by weight relative to the total weight of the composition; B) at least one oxidation base chosen from diaminopyrazolones and acid-addition salts thereof; C) at least one additional dye precursor other than the oxidation base in B); D) at least one oxidizing agent; and optionally E) at least one alkaline agent. | 07-01-2010 |
20100175203 | READY-TO-USE COMPOSITION FOR THE OXIDATION DYEING OF KERATIN FIBERS COMPRISING AT LEAST ONE FATTY SUBSTANCE, AT LEAST ONE OXIDATION CHOSEN FROM 4,5-DIAMINOPYRAZOLES AND ACID ADDITION SALTS THEREOF, AT LEAST ONE ADDITIONAL DYE PRECURSOR OTHER THAN THE AT LEAST ONE OXIDATION BASE, AT LEAST ONE OXIDIZING AGENT, AND OPTIONALLY AT LEAST ONE ALKALINE AGENT, AND PROCESSES AND KITS THEREWITH - Provided is a ready-to-use composition for the oxidation dyeing of keratin fibers, and for example human keratin fibers such as the hair, comprising: A) at least one fatty substance present in the ready-to-use composition in an amount of greater than or equal to 25% by weight relative to the total weight of the ready-to-use composition, B) at least one oxidation base chosen from 4,5-diaminopyrazoles and the acid addition salts thereof, C) at least one additional dye precursor other than the at least one oxidation base defined in B), D) at least one oxidizing agent, and optionally E) at least one alkaline agent. Also provided is a process comprising applying to the keratin fibers for a period of time sufficient to develop the desired coloring, the ready-to-use composition. | 07-15-2010 |
20100180389 | COMPOSITION COMPRISING AT LEAST ONE FATTY SUBSTANCE AND AT LEAST ONE SURFACTANT COMPRISING ETHYLENE OXIDE, DYEING OR LIGHTENING PROCESS USING IT AND DEVICES THEREFOR - The present disclosure relates to a composition for dyeing or lightening human keratin fibers, comprising:
| 07-22-2010 |
20100275388 | COMPOSITION FOR OXIDATION DYEING KERATIN FIBRES COMPRISING A CATIONIC CELLULOSE ETHER, A WEAKLY OXYETHYLENATED SORBITAN FATTY ACID ESTER AND OXIDATION DYES - The present invention relates to a dye composition comprising, in a medium suitable for dyeing: A) one or more particular cationic cellulose ether(s), B) one or more weakly oxyethylenated sorbitan fatty acid ester(s), and C) one or more oxidation dye(s). The present invention also relates to a process for dyeing keratin fibres using such a composition, and also to the use of this composition for dyeing keratin fibres. | 11-04-2010 |
Patent application number | Description | Published |
20110112613 | LOW LEVEL LASER THERAPY (LLLT) SYSTEMS AND DEVICES - A system includes a LLLT device, with a laser diode and a momentary switch, and a clip device configured to attach to the LLLT device and to press the momentary switch while attached, causing the LLLT device to activate the laser diode. A LLLT device includes a laser diode, a front end from which light radiates when the laser diode is activated, and an eye safety mechanism at the front end. The LLLT device is configured to activate the laser diode when the front end is pressed. | 05-12-2011 |
20110178583 | SCANNING MECHANISM AND TREATMENT METHOD FOR LLLT OR OTHER LIGHT SOURCE THERAPY DEVICE - A scanning mechanism to scan a light source, such as a low-level laser, to create a desirable energy distribution on a treatment area. The light source may include multiple light beam generators, each having a different wavelength and each having a different energy distribution. The scanning mechanism can be programmable to scan in different patterns in accordance with a desired treatment. | 07-21-2011 |
20120323295 | SCANNING MECHANISM AND TREATMENT METHOD FOR LLLT OR OTHER LIGHT SOURCE THERAPY - A scanning mechanism to scan a light source, such as a low-level laser, to create a desirable energy distribution on a treatment area. The light source may include multiple light beam generators, each having a different wavelength and each having a different energy distribution. The scanning mechanism can be programmable to scan in different patterns in accordance with a desired treatment. | 12-20-2012 |
20130041431 | LOW LEVEL LASER THERAPY (LLLT) SYSTEMS AND DEVICES - A system includes a LLLT device, with a laser diode and a momentary switch, and a clip device configured to attach to the LLLT device and to press the momentary switch while attached, causing the LLLT device to activate the laser diode. A LLLT device includes a laser diode, a front end from which light radiates when the laser diode is activated, and an eye safety mechanism at the front end. The LLLT device is configured to activate the laser diode when the front end is pressed. | 02-14-2013 |
20140336732 | HANDHELD LOW-LEVEL LASER THERAPY APPARATUS - A laser therapy device, including: a laser diode that is adapted to produce a monochromatic laser beam; a lens that is adapted to receive the beam directly from the laser diode and exploit the natural divergence of the laser diode to form an essentially coherent monochromatic, collimated beam; wherein the formed beam is adapted to form on a plane perpendicular to the direction of propagation of the beam an elongated illuminated area in which the length of the illuminated area is at least twice the size of the width of the illuminated area; a controller that is adapted to control activation of the laser diode; an encasement enclosing the laser diode, the lens and the controller; wherein the encasement is adapted to be hand held by the user. | 11-13-2014 |
20150202118 | NON-INVASIVE METHODS FOR PREVENTION, DETECTION, TREATMENT, AND HEALING OF NEOPLASTIC PROCESSES IN HUMANS - The invention is a method consisting of stimulation of specific new acupuncture points to prevent, detect, treat and heal specific types of neoplastic process in humans. The specific acupuncture points used in the method of the invention have not been previously disclosed for the treatment of neoplastic processes. The treatments can be carried out by accredited practitioners in a clinical setting or by the patient her/himself at home. The stimulation can be provided by any of the known techniques used for stimulation of controlling points, including, but not limited to, traditional acupuncture needles, auto-injector needles, electric acupuncture, acupressure, lasers, acupuncture lasers, UV radiation, infra-red radiation, heat, magnets, moxibustion, and a combination of two or more of these techniques, for example, the use of both needles and laser acupuncture simultaneously in a single treatment session. The method of the invention is also used for detection and prevention of neoplastic process. | 07-23-2015 |
20150202119 | NON-INVASIVE METHODS FOR PREVENTION, DETECTION, TREATMENT, AND HEALING OF NEOPLASTIC PROCESSES IN DOGS AND CATS - The invention is a method consisting of stimulation of specific new acupuncture points to prevent, treat and heal specific types of neoplastic process in dogs and cats. The specific acupuncture points used in the method of the invention have not been previously disclosed for the treatment of neoplastic processes. The treatments can be carried out by accredited practitioners in a clinical setting or by a layperson. The stimulation can be provided by any of the known techniques used for stimulation of controlling points, including, but not limited to, traditional acupuncture needles, auto-injector needles, electric acupuncture, acupressure, lasers, acupuncture lasers, UV radiation, infra-red radiation, heat, magnets, moxibustion, and a combination of two or more of these techniques, for example, the use of both needles and laser acupuncture simultaneously in a single treatment session. | 07-23-2015 |
20160136045 | GUIDING MEANS FOR ADMINISTERING ACUPUNCTURE AND OTHER HEALING PROCEDURES - The invention is guiding means that are adapted to serve as guides to accurately locate specific locations on the body to be stimulated in order to prevent, diagnose, and treat specific types of diseases and other conditions in humans and animals. The invention includes specially modified and personalized articles of clothing and an apparatus for supporting an organ of a human or animal body adapted for accurately positioning and orienting the organ with respect to each other a device for administering the stimulation or the healing process. The apparatus and embodiments of the articles of clothing are adapted as stands that support devices used to apply stimulation to the location. The applied stimulation can be any of the therapies which depend on the application of energy or force to specific locations on the body. | 05-19-2016 |